This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           February 04, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


New method shrinks metastatic ovarian cancer and reduces chemotherapy dose
Science Daily
New research published in the February 2015 issue of The FASEB Journal, may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery. This new method involves the use of a portion of a naturally occurring protein inhibitor of angiogenesis called thrombospondin-1 or TSP-1. The portion, known as 3TSR, interacts with another protein called CD36 causing cells needed for tumors to create new blood vessels (endothelial cells) to stop growing and die. In turn, this reduces the formation of new blood vessels (angiogenesis) needed for tumors to grow.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


SGO Board of Directors and Foundation Council open election
The 2015 SGO Board of Directors and Foundation Council open election is now under way. All SGO members who are eligible to vote should have received an email from on Monday, Jan. 12. The list of candidates for each position, including biographical information, personal statements and photos, is available for your consideration. Please take some time to review the candidates’ statements prior to casting your vote. Candidate information is also available on the ballot. Voting ends at 11:59 p.m. CST on Friday, Feb. 13.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Additional aromatase inhibitor may improve endometrial cancer chemotherapy effectiveness
2 minute medicine
A phase II clinical trial published in the Journal of Clinical Oncology evaluated the response of a combination therapy of an aromatase inhibitor (letrozole) and PI3K/mTOR inhibitor (everolimus) in patients with recurrent EC. The combination treatment demonstrated a clinical response rate of 40% at 16 weeks, as measured by prolonged stable disease. The safety profile of this combination was excellent as there were no patients that discontinued treatment due to toxicity. The most significant predictor of response were patients with endometrioid histology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Researchers discover genetic fingerprint of HPV virus in some head and neck cancers
Cancer Research UK
A large U.S. study published in the journal Nature has pinpointed genetic errors that mark out head and neck cancers caused by the human papillomavirus (HPV). If confirmed in further studies, this could be used to develop potential new treatments. Similarities between the DNA of head and neck tumors cells and other cancers - including squamous cell lung cancer, and cervical cancer - were also found, suggesting there may be common paths of cancer development – and potentially treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Obama gives East Room rollout to Precision Medicine Initiative
President Barack Obama recently unveiled the Precision Medicine Initiative he’ll include in his 2016 budget request to a White House East Room audience packed with federal science leaders, academic researchers, patient and research advocacy groups, congressional guests, and drug industry executives. By and large, they seemed to cheer his plan to find ways to use genomics and other molecular information to tailor patient care. After poking fun at his own knowledge of science — a model of chromosomes made from pink swim noodles “was helpful to me,” he said — Obama explained what precision medicine is: “delivering the right treatments, at the right time, every time to the right person.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Breast cancer tests betray 'Precision Medicine' branding
Yes, President Obama’s new $215 million Precision Medicine Initiative supports important science, but it also bolsters biotech branding in a way the science doesn’t always support. To understand why clinical genomics (a more neutral descriptor) isn’t quite as reliably precise as backers like to boast, consider three tests meant to determine whether a certain type of breast cancer will recur. The tests can help avoid the physical and emotional costs of unneeded chemotherapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.


Which breast cancer patients need lymph nodes removed? Ultrasound narrows it down, study finds
Science Daily
Which breast cancer patients need to have underarm lymph nodes removed? Mayo Clinic-led research is narrowing it down. A new study finds that not all women with lymph node-positive breast cancer treated with chemotherapy before surgery need to have all of their underarm nodes taken out. Ultrasound is a useful tool for judging before breast cancer surgery whether chemotherapy eliminated cancer from the underarm lymph nodes, the researchers found. The findings are published in the Journal of Clinical Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.

Is radiation therapy in early-stage breast cancer always necessary?
Radiation treatment after a lumpectomy has traditionally involved irradiation of the entire breast with an external beam over 6 weeks. Recent data, however, suggest it may be time to break tradition. A study conducted by the University of Pennsylvania Perelman School of Medicine and published in JAMA analyzed the frequency of hypofractionated whole breast irradiation (WBI) versus conventional WBI after breast-conserving surgery in the United States from 2008 through 2013. Researchers defined hypofractionated treatments as those spanning 11-24 fractions over approximately 3 weeks, and conventional as 25-40 treatments over approximately 6 weeks.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Jan. 28, 2015
Jan. 21, 2015
Jan. 14, 2015
Jan. 7, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063